Search Results - Alexandre Selmani

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age by Corwin A. Robertson, Jeffry Jacqmein, Alexandre Selmani, Katherine Galarza, Philipp Oster

    Published in Human Vaccines & Immunotherapeutics (2024-12-01)
    Get full text
    Article


  2. 2

    Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study by Corwin A. Robertson, Jeffry Jacqmein, Alexandre Selmani, Katherine Galarza, Philipp Oster

    Published in Human Vaccines & Immunotherapeutics (2023-01-01)
    Get full text
    Article


  3. 3

    Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infantsAJOG Global Reports at a Glance by Amber Hsiao, PhD, MPH, Arnold Yee, MBA, Ruvim Izikson, MD, MPH, Bruce Fireman, MA, John Hansen, MPH, Ned Lewis, MPH, Sonja Gandhi-Banga, PhD, Alexandre Selmani, PhD, Oxana Talanova, MD, MPH, Heidi Kabler, MD, Ajinkya Inamdar, MBBS, MS, MBA, Nicola P. Klein, MD, PhD

    Published in AJOG Global Reports (2024-11-01)
    Get full text
    Article


  4. 4

    Corrigendum to ‘Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants’ [AJOG Global Reports Volume 4, Issue 4, November 2024, 100395] by Amber Hsiao, PhD, MPH, Arnold Yee, MBA, Ruvim Izikson, MD, MPH, Bruce Fireman, MA, John Hansen, MPH, Ned Lewis, MPH, Sonja Gandhi-Banga, PhD, Alexandre Selmani, PhD, Oxana Talanova, MD, MPH, Heidi Kabler, MD, Ajinkya Inamdar, MBBS, MS, MBA, Nicola P. Klein, MD, PhD

    Published in AJOG Global Reports (2025-08-01)
    Get full text
    Article


Search Tools: